All News

The Company announces that it has raised £555,000 from the issue of 370,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.15p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 2 May 2012...

16 Apr

PAGE Meeting 2012

in Other News

Dr Frances Brightman and Dr Eric Fernandez have both been accepted to present at this years PAGE Meeting in Venice. They will show an update, respectively on the three-dimensional tumour cell cultures and on the anti cancer drug combination database research programs. Please click here for more information on the conference. ...

29 Mar

Physiomics to present new developments of the Virtual Tumour platform at Annual Meeting for American Association for Cancer Research (“AACR”)

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR Annual Meeting 2012, taking place at the McCormick Place West, Chicago, Illinois on March 31- April 4 2012. Dr Frances Brightman, Senior Scientist at Physiomics, will present the application of the Virtual Tumour platform to three-dimensional cell cultures...

22 Mar

Workshop Invitation – Half-day Workshop on 5th June 2012 at Palazzo del Casinò (Venice)

in Other News

“Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to optimize the outcomes of xenograft experiments”, ahead of the 2012 PAGE meeting. This workshop will review the available PK/PD models to simulate and analyze xenograft experiments and will present the features and the implementation of Physiomics’ Virtual Tumour technology with a previously published case study (for details click here). The workshop will...

07 Mar

Interim Results Statement for the six month period ended 31 December 2011

The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces the financial results for the six months ended 31 December 2011. Physiomics Plc is a computational systems biology services company, applying simulations supporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Read more...

01 Mar

New Agreement to advance oncology candidate with global pharma company

Physiomics plc is pleased to announce that it has signed a new agreement with a major global pharmaceutical company. Under the agreement, Physiomics will determine the optimal dosing and timing of a new compound currently under development by this new client, in combination with irradiation therapy. Read more...

31 Jan

Physiomics to enter new therapeutic area with appointment of SAB member

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce its intention to increase the scope of its offering through the development of a new modelling service to predict the cardiac toxicity of drugs. The Directors believe that this new service will be of particular interest to biotechnology companies looking to streamline their drug discovery programmes and improve the success rates...

26 Jan

Update on 3D Culture Collaboration with InSphero

The below excerpt has been taken from InSphero’s latest newsletter, 'Upgrade Your Cell-Based Assays to 3D', discussing the collaboration between InSphero and Physiomics plc. Customer case study: 3D microtissue growth and drug response – virtual and in vitro models InSphero’s customer Physiomics plc develops computational systems-biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The Oxford (UK)-based company has created detailed...

24 Jan

AACR Annual Meeting 2012

in Other News